The U.S. Food and Drug Administration classified the filing as a class 1 review, establishing a Prescription Drug User Fee Act target date of July 29 for a final decision. If the agency grants approval, Lytenava will become the first ophthalmic formulation of bevacizumab cleared specifically for treating wet age-related macular degeneration, a condition characterized by retinal damage and progressive vision loss.

Management has already initiated prelaunch operations in anticipation of the July deadline. The current momentum reflects investor optimism surrounding the company's prospects for capturing a new segment of the ophthalmic market.